NNLX ex-patent attorney was a smart cookie-the patents owned or assigned to NNLX should be as valid as any-any patent application which follows the rules and is validated by the patent office has the force of the rule of law ihn modern 'civilizatuion' (except in China, which built itself and it's military on the usa etc trade deficit and espionage, stealing trillions of USA etc technology).
Biotech is not in the top 1000 of subjects of my expertise but big pharma no doubt employs patent crawlers who keep track of new patents their companies might be interested in-which is one reason why it was important to register the patent in 14 european countries.
Dont know if that's how the interest of several entities referenced below initiated or not-but its much more likely than a startups PR,though big pharma certainly buys up startups who have tech they are interested in- and NNLX may have sent info to companies in the geographic areas mentioned by NNLX's latest communications.
As far as that goes, big pharma probably has sweat shops of chained speed readers 'multitaskers' fighting to get out of the dungeon to keep track of any pharma related material and could learn of NNLX info that way.
But as this board has discussed for sometime, the biggest problem is built in political and economic barriers resulting from entrenched relationships enforced by a sophisticated system of bribes and threats,wherein a large portion of the limited intelligence of humans presides in the business world- 'me me me-protect our entrenched business relationships'. It sometimes requires visionaries to move past that,and that is more a matter of chance/luck for NNLX.
As the rare intelligent decision maker executes a cost benefit analysis, incorporating the competitive real time advantages of NNLX tech,at some point some sapiens sapiens (without too much inbred blue blood or evolutionary ape or sand cat blood) with enough charisma to do something is going to decide the advantages lie with NNLX's product. Think of the doctor/administrator in The Citadel who initiated the mind blowing advance of telling doctors to wash their hands in between patients,including cadavers. That knowledge, the advantages of cleansing via running water,had been transmitted thousands of years earlier,but nobody in power in the western medical community had apparently been aware of that.
and then when one hospital etc begins saving lives -with fewer lawsuits-by using NNLX tech-that info could be a game changer in the cost benefit analysis of that hospitals competitors-who are being sued because they arent using best available affordable NNLX tech- because lawsuits do have the attention of the allopathic medical community-this stream has more to do w N-assay than petri's but also has some traction w NNLX petri tech.
emphasis below is mine:
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
Biotech is not in the top 1000 of subjects of my expertise but big pharma no doubt employs patent crawlers who keep track of new patents their companies might be interested in-which is one reason why it was important to register the patent in 14 european countries.
Dont know if that's how the interest of several entities referenced below initiated or not-but its much more likely than a startups PR,though big pharma certainly buys up startups who have tech they are interested in- and NNLX may have sent info to companies in the geographic areas mentioned by NNLX's latest communications.
As far as that goes, big pharma probably has sweat shops of chained speed readers 'multitaskers' fighting to get out of the dungeon to keep track of any pharma related material and could learn of NNLX info that way.
But as this board has discussed for sometime, the biggest problem is built in political and economic barriers resulting from entrenched relationships enforced by a sophisticated system of bribes and threats,wherein a large portion of the limited intelligence of humans presides in the business world- 'me me me-protect our entrenched business relationships'. It sometimes requires visionaries to move past that,and that is more a matter of chance/luck for NNLX.
As the rare intelligent decision maker executes a cost benefit analysis, incorporating the competitive real time advantages of NNLX tech,at some point some sapiens sapiens (without too much inbred blue blood or evolutionary ape or sand cat blood) with enough charisma to do something is going to decide the advantages lie with NNLX's product. Think of the doctor/administrator in The Citadel who initiated the mind blowing advance of telling doctors to wash their hands in between patients,including cadavers. That knowledge, the advantages of cleansing via running water,had been transmitted thousands of years earlier,but nobody in power in the western medical community had apparently been aware of that.
and then when one hospital etc begins saving lives -with fewer lawsuits-by using NNLX tech-that info could be a game changer in the cost benefit analysis of that hospitals competitors-who are being sued because they arent using best available affordable NNLX tech- because lawsuits do have the attention of the allopathic medical community-this stream has more to do w N-assay than petri's but also has some traction w NNLX petri tech.
emphasis below is mine:
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
3
